Valuation Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Stocks
600196
CNE000000X38
Pharmaceuticals
|
End-of-day quote
Shanghai S.E.
2026-11-06
|
5-day change | 1st Jan Change | ||
| 23.58 CNY | -0.34% |
|
+4.06% | -10.99% |
| 11-04 | Fosun Pharma Subsidiary Waives Right to Receive Transferred Shares in Biologics-Focused Equity Fund | MT |
| 11-04 | Fosun Pharma Unit Begins Trial of FXS6837 Capsules for Gemoglobinuria in China | MT |
Company Valuation: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 113,862 | 86,922 | 61,592 | 59,749 | 65,095 | 57,857 | - | - |
| Change | - | -23.66% | -29.14% | -2.99% | 8.95% | -11.12% | - | - |
| Enterprise Value (EV) 1 | 127,150 | 99,797 | 80,958 | 81,558 | 87,933 | 70,668 | 77,600 | 69,957 |
| Change | - | -21.51% | -18.88% | 0.74% | 7.82% | -19.63% | 9.81% | -9.85% |
| P/E | 26.5x | 24.6x | 28.1x | 23.9x | 20.9x | 17.3x | 14.5x | 13.1x |
| PBR | 3.21x | 2.11x | 1.46x | 1.41x | 1.45x | 1.23x | 1.13x | 1.05x |
| PEG | - | -1.1x | -0.7x | 1.4x | 0.9x | 2.35x | 0.8x | 1.2x |
| Capitalization / Revenue | 2.92x | 1.98x | 1.49x | 1.46x | 1.56x | 1.39x | 1.33x | 1.24x |
| EV / Revenue | 3.26x | 2.28x | 1.96x | 1.99x | 2.11x | 1.69x | 1.78x | 1.5x |
| EV / EBITDA | 14.8x | 12.4x | 13.1x | 13.5x | 10.2x | 10.5x | 11.9x | 9.18x |
| EV / EBIT | 20.1x | 30.7x | 24.5x | 29.3x | 16.8x | 27.3x | 24.7x | 18.5x |
| EV / FCF | -137x | -63.8x | -42.3x | 155x | 104x | 7.81x | 20.3x | 17.3x |
| FCF Yield | -0.73% | -1.57% | -2.36% | 0.64% | 0.96% | 12.8% | 4.94% | 5.79% |
| Dividend per Share 2 | 0.56 | 0.42 | 0.27 | 0.32 | 0.39 | 0.426 | 0.4882 | 0.5549 |
| Rate of return | 1.14% | 1.19% | 1.08% | 1.29% | 1.47% | 1.81% | 2.07% | 2.35% |
| EPS 2 | 1.85 | 1.43 | 0.89 | 1.04 | 1.27 | 1.363 | 1.626 | 1.797 |
| Distribution rate | 30.3% | 29.4% | 30.3% | 30.8% | 30.7% | 31.2% | 30% | 30.9% |
| Net sales 1 | 39,005 | 43,811 | 41,400 | 40,910 | 41,662 | 41,706 | 43,532 | 46,610 |
| EBITDA 1 | 8,569 | 8,041 | 6,160 | 6,022 | 8,585 | 6,750 | 6,496 | 7,619 |
| EBIT 1 | 6,314 | 3,253 | 3,308 | 2,780 | 5,228 | 2,587 | 3,140 | 3,777 |
| Net income 1 | 4,735 | 3,737 | 2,386 | 2,770 | 3,371 | 3,530 | 4,310 | 4,769 |
| Net Debt 1 | 13,289 | 12,875 | 19,366 | 21,810 | 22,838 | 12,811 | 19,743 | 12,100 |
| Reference price 2 | 48.94 | 35.24 | 25.03 | 24.85 | 26.49 | 23.58 | 23.58 | 23.58 |
| Nbr of stocks (in thousands) | 2,562,899 | 2,672,157 | 2,672,399 | 2,658,090 | 2,639,554 | 2,657,968 | - | - |
| Announcement Date | 3/22/22 | 3/27/23 | 3/26/24 | 3/25/25 | 3/24/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 17.3x | 1.69x | 10.47x | 1.81% | 8.66B | |
| 39.62x | 13.42x | 28.51x | 0.5% | 1,206B | |
| 40.43x | 6.79x | 19.09x | 1.93% | 665B | |
| 37.52x | 8.51x | 17.57x | 2.38% | 515B | |
| 20.98x | 5.12x | 12.74x | 2.57% | 381B | |
| 97.18x | 5.94x | 25.33x | 2.32% | 362B | |
| 23.18x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.46x | 4.89x | 13.77x | 1.79% | 289B | |
| 23.75x | 7.3x | 13.55x | 2.19% | 249B | |
| -39.18x | 7.28x | 45.82x | 1.98% | 207B | |
| Average | 28.52x | 6.69x | 20.12x | 2.01% | 418.84B | |
| Weighted average by Cap. | 35.64x | 8.54x | 21.84x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 600196 Stock
- Valuation Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
